Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

CONSORT flow diagram. by Judith I. Tsui (5983160)

Adverse events in placebo arm. by Judith I. Tsui (5983160)

Adverse events in gabapentin arm. by Judith I. Tsui (5983160)

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Crosslinking decreases the alignment of fibers associated with individual cells migrating out of spheroids. by Michael Pamonag (12295175)

CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

“…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”

Apicoplast inhibitors decrease global parasite prenylation in the second IDC after treatment. by Kit Kennedy (4915510)

Experimental protocol. by Hiroyuki Matsuta (13250169)

Visualization of the primary motor network analyzed using FSL MELODIC. by Hiroyuki Matsuta (13250169)

Fig 3 - by Hiroyuki Matsuta (13250169)

ST2-104 decreases the Aβ_25-35-mediated increase in intracellular Ca²⁺. by Yingshi Ji (9013004)

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Random forest plot showing the importance of predictors (top 10) for classifying LF progression based on the Mean Decrease in Gini index. by Emmanuel Kobla Atsu Amewu (13946765)

Multiple trauma and hemorrhagic shock induce a transcriptional immune response. by Marc-Alexander Oestreich (13961375)

Mean (±95%CI) 24-hr post soreness measured using a numeric pain rating scale (1–10) for the Nordic hamstring exercise, Sprint, and control groups. by Nicholas J. Ripley (14709756)